Peter M. Barth

Peter M. Barth

Department Of Medicine, Alpert Medical School Of Brown University, Providence, Ri

Direct Impact

Concepts for which Peter M Barth has direct influence:

secondary polycythemia
first-line lenalidomide
older adults
bone-modifying agents
adjuvant nivolumab
primary malignancy
anal cancer

External impact

Concepts related to the work of other authors for which Peter M Barth has influence:

international field
disease-specific questionnaire module
combination chemotherapy
extramammary paget
oral anticancer agents
financial assistance
lymph nodes

Prominent publications by Peter M. Barth

KOL-Index: 27 The therapeutic armamentarium for multiple myeloma has grown significantly over the past decade. We characterized ongoing multiple myeloma clinical trials utilizing . A search of on 21 April 2017 returned 239 therapeutic interventional trials in multiple myeloma. A majority (84.1%) of trials are early-phase (I/II). Immunotherapies are significantly more ...
Known for
21 April | Ongoing Trials | Late-Phase | Early-Phase
KOL-Index: 25 Extramammary Paget's disease (EMPD) is a rare cancer. Although EMPD is usually noninvasive and treated with local therapy, once metastatic the prognosis of EMPD is poor and treatment options are limited. We report a case of a complete response to single agent trastuzumab in a hemodialysis patient with metastatic Her2/neu overexpressed EMPD of the scrotum. Molecular profiling of his case as ...
Known for
Extramammary Pagets | Hemodialysis Metastatic | Her2 Targeted Agents | Mpd
KOL-Index: 15 BACKGROUND: Patients with cancer experience stress surrounding diagnosis and treatment. Many cancer centers employ a nurse-led education session to alleviate patient anxiety and confusion. . OBJECTIVES: The goal was to evaluate the effect of a nurse-led chemotherapy teaching session on patients' knowledge, anxiety, and preparedness for cancer-directed therapy. . METHODS: After discussing ...
Known for
Education Session | Cycle Therapy | Nurse Survey
KOL-Index: 12 BACKGROUND: Guidelines recommend bone-modifying agents (BMAs) for all patients initiating treatment for myeloma. We examined adherence to this recommendation, and BMA effectiveness in the era of bortezomib/lenalidomide-based therapy among Medicare beneficiaries. METHODS: From the linked Surveillance, Epidemiology, and End Results-Medicare registry, we selected beneficiaries receiving ...
Known for
Contemporary Anti-Myeloma Regimens | Proportional Hazard Models | Skeletal-Related | Immortal-Time Bias
KOL-Index: 11 Introduction: Secondary polycythemia is a disorder of increased hemoglobin or hematocrit most often resulting from states of systemic hypoxia such as chronic obstructive pulmonary disease (COPD). Many patients with secondary polycythemia are treated with phlebotomy to reduce hematocrit levels based on recommendations for polycythemia vera (PV)-a myeloproliferative neoplasm characterized by ...
Known for
Phlebotomy Hematocrit | Arterial Thrombotic | Jak2 Allele | Increased Hemoglobin
KOL-Index: 11 INTRODUCTION: The treatment of renal cell carcinoma (RCC) has undergone a major shift over the past 10 years and continues to evolve. The objective of this study was to assess the current landscape of clinical trials (CTs) in RCC to identify areas of strength and opportunities for improvement. MATERIALS AND METHODS: was queried using 17 prespecified search criteria. Only ...
Known for
Trials Renal | Examined Cts | Point Sponsorship
KOL-Index: 9 BACKGROUND: Therapeutic advances have extended survival for patients with myeloma, who may develop secondary cancers. METHODS: Using the population-based Surveillance, Epidemiology, and End Results registry (2004-2015), the authors examined the characteristics, overall and cause-specific survival, and cumulative incidence function of cancer-related death among patients with myeloma with ...
Known for
Cause-Specific Survival | Myeloma-Related Deaths | Studied Solid Tumor | Stage Differ
KOL-Index: 7 The "triplet" regimen of lenalidomide, bortezomib, and dexamethasone (RVD) showed survival advantage over lenalidomide-dexamethasone (RD) in clinical trials, but older patients with myeloma often receive doublet regimens (RD or bortezomib-dexamethasone, VD), or VD plus cyclophosphamide (VCD). We compared these first-line regimens using real-world data from Medicare beneficiaries receiving ...
KOL-Index: 5 OBJECTIVES: Clinical trials have suggested that patients with myeloma treated with lenalidomide may have an increased risk of second primary malignancies (SPM). Whether such risks are of significant relevance in the real-world clinical practice, particularly among older patients receiving first-line lenalidomide based therapy, remains unclear. METHODS: Using Surveillance Epidemiology and End ...
Known for
Results-Medicare | Malignancy Older | 361 Solid Tumors | 65 Years

Department of Medicine, Alpert Medical School of Brown University, Providence, RI

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172